BRPI0410488A - composição farmacêutica lìquida estabilizada livre de hsa, método para preparação de composição farmacêutica lìquida estabilizada livre de hsa, recipiente vedado hermeticamente e kit para administração de múltiplas doses de composição farmacêutica lìquida estabilizada livre de hsa' - Google Patents

composição farmacêutica lìquida estabilizada livre de hsa, método para preparação de composição farmacêutica lìquida estabilizada livre de hsa, recipiente vedado hermeticamente e kit para administração de múltiplas doses de composição farmacêutica lìquida estabilizada livre de hsa'

Info

Publication number
BRPI0410488A
BRPI0410488A BRPI0410488-9A BRPI0410488A BRPI0410488A BR PI0410488 A BRPI0410488 A BR PI0410488A BR PI0410488 A BRPI0410488 A BR PI0410488A BR PI0410488 A BRPI0410488 A BR PI0410488A
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
liquid pharmaceutical
stabilized liquid
free stabilized
hsa
Prior art date
Application number
BRPI0410488-9A
Other languages
English (en)
Inventor
Fabrizio Samaritani
Alessandra Del Rio
Original Assignee
Ares Trading Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading Sa filed Critical Ares Trading Sa
Publication of BRPI0410488A publication Critical patent/BRPI0410488A/pt
Publication of BRPI0410488B1 publication Critical patent/BRPI0410488B1/pt
Publication of BRPI0410488B8 publication Critical patent/BRPI0410488B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

"COMPOSIçãO FARMACêUTICA LìQUIDA ESTABILIZADA LIVRE DE HSA, MéTODO PARA PREPARAçãO DE COMPOSIçãO FARMACêUTICA LìQUIDA ESTABILIZADA LIVRE DE HSA, RECIPIENTE VEDADO HERMETICAMENTE E KIT PARA ADMINISTRAçãO DE MúLTIPLAS DOSES DE COMPOSIçãO FARMACêUTICA LìQUIDA ESTABILIZADA LIVRE DE HSA". Descreve uma composição farmacêutica líquida estabilizada livre de HSA, que é composta de um interferon (IFN), caracterizada pelo fato de que a referida formulação seja uma solução que seja composta de um tampão, um surfactante, um agente de isotonicidade e um antioxidante. Preferivelmente, o interferon é um recombinante humano IFN-beta.
BRPI0410488A 2003-05-01 2004-04-29 Composição farmacêutica líquida estabilizada e livre de hsa, método para preparação de composição farmacêutica líquida estabilizada e livre de hsa, e recipiente vedado hermeticamente BRPI0410488B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP03101210.7 2003-05-01
EP03101210 2003-05-01
US53016903P 2003-12-17 2003-12-17
US60/530,169 2003-12-17
PCT/EP2004/004806 WO2004096263A2 (en) 2003-05-01 2004-04-29 Human serum albumin-free stabilized interferon liquid formulations

Publications (3)

Publication Number Publication Date
BRPI0410488A true BRPI0410488A (pt) 2006-06-13
BRPI0410488B1 BRPI0410488B1 (pt) 2021-06-22
BRPI0410488B8 BRPI0410488B8 (pt) 2021-09-08

Family

ID=36908159

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0410488A BRPI0410488B8 (pt) 2003-05-01 2004-04-29 Composição farmacêutica líquida estabilizada e livre de hsa, método para preparação de composição farmacêutica líquida estabilizada e livre de hsa, e recipiente vedado hermeticamente

Country Status (28)

Country Link
US (1) US8309069B2 (pt)
EP (1) EP1617861B1 (pt)
JP (2) JP4870550B2 (pt)
KR (1) KR101116058B1 (pt)
CN (1) CN1816347B (pt)
AR (1) AR044147A1 (pt)
AU (2) AU2004233603B2 (pt)
BR (1) BRPI0410488B8 (pt)
CA (1) CA2521560A1 (pt)
DK (1) DK1617861T3 (pt)
EA (2) EA009995B1 (pt)
ES (1) ES2417061T3 (pt)
HR (1) HRP20130512T1 (pt)
IL (1) IL171709A (pt)
ME (1) ME00404B (pt)
MX (1) MXPA05011718A (pt)
MY (1) MY151121A (pt)
NO (1) NO335674B1 (pt)
NZ (2) NZ542912A (pt)
PL (1) PL1617861T3 (pt)
PT (1) PT1617861E (pt)
RS (1) RS52869B (pt)
SG (1) SG159389A1 (pt)
SI (1) SI1617861T1 (pt)
TW (1) TWI272948B (pt)
UA (2) UA80331C2 (pt)
WO (1) WO2004096263A2 (pt)
ZA (2) ZA200508124B (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7846427B2 (en) * 2003-12-11 2010-12-07 Ares Trading S.A. Stabilized interferon liquid formulations
ZA200609412B (en) * 2004-05-17 2008-07-30 Ares Trading Sa Hydrogel interferon formulations
EP1750751B1 (en) * 2004-06-01 2013-04-10 Ares Trading S.A. Stabilized interferon liquid formulations
BRPI0510527A (pt) * 2004-06-01 2007-10-30 Ares Trading Sa método de estabilização de proteìnas
JP4897814B2 (ja) * 2005-09-14 2012-03-14 アレス トレーディング ソシエテ アノニム ポロキサマーの定量方法
MX2008014971A (es) 2006-05-24 2008-12-05 Serono Lab Regimen de cladribine para tratar esclerosis multiple.
WO2008066322A1 (en) * 2006-11-28 2008-06-05 Daewoong Co., Ltd. A stable hsa-free and antioxidant-free pharmaceutical composition comprising interferon-beta
WO2008065752A1 (fr) * 2006-11-30 2008-06-05 National University Corporation Hokkaido University Agent immunothérapeutique contenant un arndi en tant que principe actif
HUE033256T2 (hu) 2007-03-30 2017-11-28 Xisle Pharma Ventures Trust Kétfázisú lipidvezikulum készítmény és eljárás cervikális diszplázia kezelésére intravaginális adagolással
WO2008145323A1 (en) * 2007-05-31 2008-12-04 F. Hoffmann-La Roche Ag Pharmaceutical formulation for interferons
ES2387236T3 (es) * 2007-12-20 2012-09-18 Merck Serono S.A. Formulaciones de interferón beta pegilado
KR20150074167A (ko) 2012-10-26 2015-07-01 루핀 리미티드 Ｐｅｇ 인터페론 알파-2ｂ의 안정한 약학 조성물
US8986732B2 (en) 2013-08-12 2015-03-24 Helix Biopharma Corporation Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery
US10159646B2 (en) 2013-08-12 2018-12-25 Altum-Avro Pharma Partnership Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery
CN107073080A (zh) * 2014-09-23 2017-08-18 豪夫迈·罗氏有限公司 包含α‑型干扰素的稳定的不含苄醇的水溶液制剂
US9925233B2 (en) 2015-01-30 2018-03-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9750785B2 (en) 2015-01-30 2017-09-05 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9687526B2 (en) 2015-01-30 2017-06-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744209B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744239B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9937223B2 (en) 2015-01-30 2018-04-10 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
KR101943160B1 (ko) * 2016-10-06 2019-01-30 에이비온 주식회사 인터페론 베타 변이체의 안정화 제제
CN111356460A (zh) 2017-11-24 2020-06-30 默克专利股份公司 用于治疗进展型形式的多发性硬化症的克拉屈滨疗法
CA3194812A1 (en) 2020-09-10 2022-03-17 Merck Patent Gmbh Novel treatment regimen for the treatment of autoimmune disorders
KR20240118230A (ko) * 2023-01-26 2024-08-05 에이비온 주식회사 인터페론 베타 건조 분말 제제 및 이의 제조방법

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US5116943A (en) 1985-01-18 1992-05-26 Cetus Corporation Oxidation-resistant muteins of Il-2 and other protein
US5017691A (en) 1986-07-03 1991-05-21 Schering Corporation Mammalian interleukin-4
US4879111A (en) 1986-04-17 1989-11-07 Cetus Corporation Treatment of infections with lymphokines
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
IT1272252B (it) * 1994-05-16 1997-06-16 Applied Research Systems Formulazioni liquide di interferone beta
TW426523B (en) * 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
ZA9610374B (en) * 1995-12-11 1997-06-23 Elan Med Tech Cartridge-based drug delivery device
KR101042660B1 (ko) 1996-12-24 2011-06-20 바이오겐 아이덱 엠에이 인코포레이티드 안정한 액체 인터페론 제제
US6013253A (en) 1997-08-15 2000-01-11 Amgen, Inc. Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist
DE59805732D1 (de) * 1997-09-23 2002-10-31 Rentschler Biotech Gmbh Flüssige interferon-beta-formulierungen
JP2001526033A (ja) * 1997-12-08 2001-12-18 ジェネンテク・インコーポレイテッド ヒトインターフェロン−イプシロンというｉ型インターフェロン
BR9910023A (pt) 1998-04-28 2000-12-26 Applied Research Systems Conjugados de poliol-ifn-beta
EP1852424B1 (de) * 1998-05-11 2012-04-04 Basf Se Verfahren zur Herstellung von Isoxazolin-3-YL-Acylbenzolen
CN1175901C (zh) 1999-12-06 2004-11-17 天津华立达生物工程有限公司 一种稳定的干扰素水溶液
US6465425B1 (en) * 2000-02-10 2002-10-15 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins
US6887462B2 (en) * 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
UY27373A1 (es) * 2001-07-09 2003-02-28 Schering Ag Formulaciones de interferón beta-humano
US7846427B2 (en) 2003-12-11 2010-12-07 Ares Trading S.A. Stabilized interferon liquid formulations
ZA200609412B (en) 2004-05-17 2008-07-30 Ares Trading Sa Hydrogel interferon formulations
BRPI0510527A (pt) 2004-06-01 2007-10-30 Ares Trading Sa método de estabilização de proteìnas

Also Published As

Publication number Publication date
SG159389A1 (en) 2010-03-30
WO2004096263A3 (en) 2004-12-02
BRPI0410488B8 (pt) 2021-09-08
JP2006525280A (ja) 2006-11-09
NZ542912A (en) 2008-04-30
HRP20130512T1 (hr) 2013-07-31
WO2004096263A2 (en) 2004-11-11
KR20060011976A (ko) 2006-02-06
AR044147A1 (es) 2005-08-24
UA94032C2 (ru) 2011-04-11
IL171709A (en) 2016-03-31
CN1816347B (zh) 2010-07-21
TWI272948B (en) 2007-02-11
TW200503754A (en) 2005-02-01
RS52869B (sr) 2013-12-31
AU2004233603A1 (en) 2004-11-11
NO20055666L (no) 2005-11-30
RS20050821A (sr) 2007-12-31
EA009995B1 (ru) 2008-06-30
MXPA05011718A (es) 2006-01-23
ME00404B (me) 2011-10-10
PT1617861E (pt) 2013-08-28
UA80331C2 (en) 2007-09-10
MEP60408A (en) 2011-05-10
JP2011225599A (ja) 2011-11-10
HK1088847A1 (zh) 2006-11-17
BRPI0410488B1 (pt) 2021-06-22
EP1617861A2 (en) 2006-01-25
ES2417061T3 (es) 2013-08-05
DK1617861T3 (da) 2013-07-29
NZ566625A (en) 2010-02-26
KR101116058B1 (ko) 2012-04-12
EA200800327A1 (ru) 2008-10-30
AU2004233603B2 (en) 2009-02-26
PL1617861T3 (pl) 2013-10-31
CN1816347A (zh) 2006-08-09
AU2009201261A1 (en) 2009-04-23
EA200501699A1 (ru) 2006-06-30
ZA200708484B (en) 2008-10-29
NO335674B1 (no) 2015-01-19
MY151121A (en) 2014-04-30
JP5346065B2 (ja) 2013-11-20
EP1617861B1 (en) 2013-05-29
US20070059285A1 (en) 2007-03-15
CA2521560A1 (en) 2004-11-11
SI1617861T1 (sl) 2013-09-30
JP4870550B2 (ja) 2012-02-08
ZA200508124B (en) 2009-02-25
US8309069B2 (en) 2012-11-13

Similar Documents

Publication Publication Date Title
BRPI0410488A (pt) composição farmacêutica lìquida estabilizada livre de hsa, método para preparação de composição farmacêutica lìquida estabilizada livre de hsa, recipiente vedado hermeticamente e kit para administração de múltiplas doses de composição farmacêutica lìquida estabilizada livre de hsa'
ES2569949T3 (es) Formulaciones farmacéuticas que comprenden un péptido complejado con una dicetopiperazina
BRPI0412241A (pt) formulação para medicamentos de proteìna sem adição de albumina de soro humano (hsa)
AR044302A1 (es) Formulaciones con proteinas liquidas estabilizadas en recipientes farmaceuticos
CY1112193T1 (el) Σταθεροποιημενα υγρα σκευασματα ιντερφερονης
MXPA02006679A (es) Composicion farmaceutica.
ES2190244T3 (es) Uso de la hormona paratiroidea constituida por una secuencia de aminoacidos 1-34 de la hormona paratiroidea humana para reducir el riesco de fracturas oseas vertebrales y no vertebrales.
PE20020968A1 (es) Preparados de insulina exentos de zinc y pobres en zinc, con estabilidad mejorada
ES2162927T3 (es) Formulacion para la aplicacion por inhalacion.
BR0215380A (pt) Pó micronizado farmacêutico ou nutracêutico de liberação imediata e utilização do mesmo
DK395689D0 (da) Pharmaceutisk tilberedning til behandling af diabetes mellitus
EP1750751B1 (en) Stabilized interferon liquid formulations
WO2003028757A1 (en) Novel method of inducing antigen-specific t cells
AR043418A1 (es) Formulaciones liquidas de las proteinas de union del factor necrosis del tumor
TW200501977A (en) Stabilized composition comprising protein
CY1108402T1 (el) Φαρμακευτικο μεσο που περιεχει μια αντιφλεγμονωδη δραστικη ουσια και υδρολυμα λακταλβουμινης και χρηση αυτου
ATE223700T1 (de) Ramoplaninhaltige neue injizierbare arzneizubereitungen
BR0202759A (pt) Composição farmacêutica de liberação modificada contendo bupropiona como substância ativa
TH102367B (th) สูตรผสมอินเตอร์เฟียรอนที่เป็นของเหลวซึ่งถูกทำให้เสถียรโดยปลอด hsa
ECSP982660A (es) USO DE ANALOGOS DEL PTHrP EN LA CICATRIZACION DE FRACTURAS

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/04/2004, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, , QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2633 DE 22/06/2021 QUANTO AOS DESENHOS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B21H Decision of lapse of a patent or of a certificate of addition of invention cancelled [chapter 21.8 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 21.6 NA RPI NO 2825 DE 25/02/2025 POR TER SIDO INDEVIDA.